Auris Medical Holding Ltd.
(NASDAQ : EARS)

( )
EARS After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
-0.69%183.171.3%$509.31m
CELGCelgene Corporation
-0.84%92.411.3%$442.42m
ARRYArray BioPharma Inc.
-0.20%46.128.1%$426.45m
GILDGilead Sciences, Inc.
-2.63%66.680.9%$400.32m
BIIBBiogen Inc.
-0.92%238.071.3%$377.86m
ILMNIllumina, Inc.
-0.48%356.373.5%$303.03m
REGNRegeneron Pharmaceuticals, Inc.
-2.50%305.082.6%$243.93m
VRTXVertex Pharmaceuticals Incorporated
-1.38%177.661.9%$210.42m
ALXNAlexion Pharmaceuticals, Inc.
0.15%125.342.0%$206.43m
EXASExact Sciences Corporation
1.20%112.7924.1%$187.08m
AAgilent Technologies, Inc.
-0.46%72.181.6%$154.39m
BMRNBioMarin Pharmaceutical Inc.
-1.04%82.954.3%$124.74m
SRPTSarepta Therapeutics, Inc.
3.37%128.3414.7%$119.55m
INCYIncyte Corporation
-2.26%85.632.5%$112.69m
MRTXMirati Therapeutics Inc.
-2.09%100.012.5%$104.17m

Company Profile

Auris Medical Holding Ltd. engages in the development of novel products that address unmet medical needs in neurotology and central nervous system disorders. The firm focuses on the development of intranasal betahistine for the treatment of vertigo and for the prevention of antipsychotic-induced weight gain and somnolence. It also includes other programs under development such as Keyzilen, for the treatment of acute inner ear tinnitus; and Sonsuvi, for the treatment of acute inner ear hearing loss. The company was founded by Thomas Meyer in April 2003 and is headquartered in Hamilton, Bermuda.